Comparative safety analysis of bevacizumab and alkylating agent in glioblastoma management – What have we learned recently?
Our analysis indicates that bevacizumab exhibits a distinct safety profile compared to alkylating agents, particularly demonstrating a lower incidence of hematological adverse events. Further prospective studies are warranted to validate these findings and to elucidate the underlying mechanisms responsible for the observed adverse events.
Authors
- Zhizhao Qu
- Jiajia Zhao (ORCID: https://orcid.org/0000-0001-8899-6356)
- Jinchuan Li (ORCID: https://orcid.org/0000-0002-4588-7798)
- Yuanwei Fu
- Yang Liu (ORCID: https://orcid.org/0000-0002-5500-1807)
- Hongqin Wang (ORCID: https://orcid.org/0000-0001-7984-3550)
- Rui Bai
Institutions
- Shanxi Medical University (CN)
- First Hospital of Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.3389/fphar.2025.1595642
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63